Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Abacavir Sulfate

FDA-approved product (tablet, oral), marketed as Abacavir Sulfate, Ziagen.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Abacavir Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • Immunodeficiency disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF06

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Abacavir Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Abacavir Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment

    NCT00005017

    Registered record
    Registry ID
    NCT00005017
    Conditions
    HIV Infections
    Interventions
    Ritonavir; Abacavir sulfate; Amprenavir; Efavirenz; Lamivudine; Stavudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRitonavir; Abacavir sulfate; Amprenavir; Efavirenz +2 more
    PhasePhase 4
    Registry statusUnknown

  • Blood Levels of Abacavir After One Dose in HIV-Infected Children and Adolescents

    NCT00011479

    Registered record
    Registry ID
    NCT00011479
    Conditions
    HIV Infections
    Interventions
    Abacavir sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2002-08
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAbacavir sulfate
    PhasePhase 1
    Registry statusCompleted

  • Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

    NCT00021463

    Registered record
    Registry ID
    NCT00021463
    Conditions
    HIV Infections; Lipodystrophy
    Interventions
    Abacavir sulfate, Lamivudine and Zidovudine; Abacavir sulfate; Efavirenz; Nevirapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    342

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Lipodystrophy
    InterventionAbacavir sulfate, Lamivudine and Zidovudine; Abacavir sulfate; Efavirenz; Nevirapine
    PhasePhase 2
    Registry statusCompleted

  • Increasing HAART-Induced Immune Restoration With Cyclosporine

    NCT00031070

    Registered record
    Registry ID
    NCT00031070
    Conditions
    HIV Infections
    Interventions
    Abacavir sulfate, Lamivudine and Zidovudine; Cyclosporine; Hepatitis A Vaccine (Inactivated); Efavirenz; Pneumococcal Conjugate Vaccine, Heptavalent; Rabies Vaccine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2006-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAbacavir sulfate, Lamivudine and Zidovudine; Cyclosporine; Hepatitis A Vaccine (Inactivated); Efavirenz +2 more
    PhasePhase 2
    Registry statusCompleted

  • A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy

    NCT00102206

    Registered record
    Registry ID
    NCT00102206
    Conditions
    HIV Infections
    Interventions
    Abacavir sulfate; Emtricitabine; Lamivudine; Lopinavir/ritonavir; Saquinavir; Tenofovir disoproxil fumarate; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2007-05
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAbacavir sulfate; Emtricitabine; Lamivudine; Lopinavir/ritonavir +3 more
    PhasePhase 2
    Registry statusCompleted